Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.61 |
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.49 |
| ▸ | THRA | P10827 | 8/20 | 0.48 |
| ▸ | THRB | P10828 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115849 | 0.89 | EGLN1 (0.77) | EGLN1EGLN2THRATHRB | |
| SCHEMBL523875 | 0.88 | EGLN1 (0.79) | EGLN1EGLN2THRATHRB | |
| SCHEMBL15549041 | 0.88 | EGLN1 (0.75) | EGLN1EGLN2THRATHRB | |
| SCHEMBL15549510 | 0.88 | EGLN1 (0.75) | EGLN1EGLN2THRATHRB | |
| Water SCHEMBL15548472 | 0.88 | EGLN1 (0.75) | EGLN1EGLN2THRATHRB | |
| SCHEMBL15547656 | 0.87 | EGLN1 (0.64) | EGLN1EGLN2THRATHRB | |
| SCHEMBL15547171 | 0.86 | EGLN1 (0.60) | EGLN1EGLN2THRATHRB | |
| SCHEMBL522574 | 0.82 | EGLN1 (0.66) | EGLN1EGLN2THRATHRB | |
| SCHEMBL27755793 | 0.82 | EGLN1 (0.66) | EGLN1EGLN2THRATHRB | |
| SCHEMBL1115578 | 0.81 | EGLN1 (0.67) | EGLN1EGLN2THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| EP-2035000-A1 | HIF HYDROXYLASE INHIBITORS FOR TREATMENT OF ANEMIA OF CANCER | FIBROGEN, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1991269-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF STROKE | FIBROGEN, INC. (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007146438-A1 | HIF HYDROXYLASE INHIBITORS FOR TREATMENT OF ANEMIA OF CANCER | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007097929-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF STROKE | FIBROGEN, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007047194-A2 | METHODS FOR TREATING MITF-RELATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |